Essential Hypertension Clinical Trial
Official title:
An Observational Study to Identify BEnefits After 24 Weeks of NEBILET®(Nebivolol) Administration For Essential hypertensIon Patients With Various Co-morbidities and Treatment Environments in KOREA.
The purpose of this study is:
To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with
other antihypertensive agents, in the control of BP and in the metabolic profile of patients
with essential hypertension (with or without co-morbidities) after 12 weeks and 24 weeks.
Nebivolol, the third-generation beta-blocker with vasodilatory effect, potentiates nitric
oxide by activating the synthesis of nitric oxide of vascular endothelial cells and improves
the function of vascular endothelial cells by reducing oxidation stress. The efficacy of
NEBILET®(Nebivolol) has been demonstrated in randomized controlled trials not only as
monotherapy but also as add-on therapy with angiotensin-converting-enzyme inhibitor,
angiotensin II receptor blocker, diuretic and other anti-hypertensive agents in lowering the
blood pressure.
Based on previous study results mentioned above, the present study aims to observe the effect
of NEBILET®(Nebivolol) on controlling blood pressure and metabolic profile change in Korean
patients with hypertension under routine clinical practice.
In addition, this study aims to identify additional benefits of NEBILET®(Nebivolol)
administration in patients with essential hypertension under various treatment environments
and existing co-morbidities in Korea, expected to provide detailed information about efficacy
of blood pressure control, lipid and carbohydrate metabolism of NEBILET®(Nebivolol)
administration in Korean patients with essential hypertension.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03708601 -
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
|
||
| Not yet recruiting |
NCT05503953 -
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
|
Phase 3 | |
| Recruiting |
NCT05526703 -
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
|
Phase 3 | |
| Completed |
NCT02890173 -
Study of CS-3150 in Patients With Essential Hypertension
|
Phase 3 | |
| Completed |
NCT02944734 -
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
|
Phase 2 | |
| Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
| Recruiting |
NCT01956786 -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
|
Phase 2/Phase 3 | |
| Completed |
NCT02553512 -
Helius in Hypertension-I: The UK Hypertension Registry
|
N/A | |
| Completed |
NCT01198249 -
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
|
Phase 1 | |
| Completed |
NCT01001572 -
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
|
Phase 3 | |
| Recruiting |
NCT00380289 -
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
|
N/A | |
| Completed |
NCT00139698 -
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
|
Phase 3 | |
| Completed |
NCT00288184 -
Uric Acid in Essential Hypertension in Children
|
Phase 2 | |
| Completed |
NCT01289886 -
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06041529 -
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
|
Phase 4 | |
| Completed |
NCT04470830 -
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
|
||
| Completed |
NCT00758524 -
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
|
Phase 2 | |
| Recruiting |
NCT05109013 -
Juvenile Essential Arterial Hypertension and Vascular Function
|
||
| Completed |
NCT00741585 -
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
|
Phase 4 | |
| Active, not recruiting |
NCT05843682 -
Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2
|
N/A |